ユーザーIDをお忘れですか? or パスワードをお忘れですか?

東京ビッグサイト | 有明

2018年11月11日 (日) 午前 9:30 - 2018年11月13日 (火) 午後 5:40

〒135-0063, 東京都江東区有明3-11-1



[V6-S2] Think about the Exit Strategy in Drug Discovery Processes of Academia

Session Chair(s)

Kotone  Matsuyama, RPh

Kotone Matsuyama, RPh

Professor, Department of Health Policy and Management

Nippon Medical School, Japan

In recent years, industry-academia collaboration has progressed in the field of drug / medical device development, and worldwide innovative new drug / treatment method from domestic academia has become a reality. When Academia conducts drug discovery research, it is important that both company and academia collaborate with early stages of development, because it will be manufactured and sold by a company, finally. However, academia researchers are not professionals of development, and there are cases where it is difficult to negotiate before cooperation. In this session, we will clarify the “gap between what each other wishes and what is required”, and also based on actual examples overcoming this, we will discuss the ideal way of cooperation approaches of industry, government, academia from their respective perspectives.


Hisashi  Koike, PhD

Role of PMDA for Drug Development

Hisashi Koike, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Review Director, Office of New Drug IV

Hiroshi  Hayashi, MS

Actual Developmental Strategy for Regenerative Medicine Products

Hiroshi Hayashi, MS

Hokkaido University Hospital, Japan

Clinical Research and Medical Innovation Center

Tetsuji  Sanuki, MD, PhD

First SAKIGAKE Designated Medical Device to Treat Adductor Spasmodic Dysphonia

Tetsuji Sanuki, MD, PhD

Nagoya City University, Japan

Associate Professor, Graduate School of Medical Sciences

Yuki  Otsuka

Yuki Otsuka

Tohoku University Hospital, Japan

Clinical Research Innovation and Education Center Tohoku University Hospital

Shinichi  Torii

Shinichi Torii

Biogen Japan Ltd., Japan